FIELD: pharmaceuticals.
SUBSTANCE: present invention refers to a combination containing Tasquinimod or its pharmaceutically acceptable salt and PD-1 and/or PD-L1 inhibitor for use as a drug. Disclosed is use of a combination comprising Tasquinimod or a pharmaceutically acceptable salt thereof and an anti-PD-1 and/or PD-L1 antibody, for treating bladder cancer. What is also presented is a pharmaceutical composition containing said combination, a combined preparation, kit and method of treating bladder cancer using said combination.
EFFECT: technical result is the disclosed combination of Tasquinimod or its pharmaceutically acceptable salt and the anti-PD-1 and/or PD-L1 antibody blocks the tumor proliferation in a synergetic way.
23 cl, 9 dwg, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF INHIBITING PD-1/PD-L1 SIGNALING PATHWAY IN BLADDER CANCER CELLS | 2023 |
|
RU2812805C1 |
| ABX196 FOR USE IN TREATMENT OF BLADDER CANCER | 2018 |
|
RU2778812C2 |
| COMBINATION OF PD-1 ANTAGONIST AND IDO1 INHIBITOR FOR TREATING ANCER | 2015 |
|
RU2744880C1 |
| REDUCTION OF TUMOR MASS BY INJECTING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | 2017 |
|
RU2745195C2 |
| COMBINATION THERAPY WITH A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | 2018 |
|
RU2796863C2 |
| BIOMARKERS AND METHODS OF TREATING PD-1 AND PD-L1 RELATED CONDITIONS | 2014 |
|
RU2820869C1 |
| BIOMARKERS AND METHODS OF TREATING ASSOCIATED WITH PD-1 AND PD-L1 CONDITIONS | 2014 |
|
RU2701378C2 |
| TREATING CANCER WITH COMBINATION OF PD-1 ANTAGONIST AND DINACICLIB | 2014 |
|
RU2705795C2 |
| COMPOSITION FOR PREVENTING OR TREATING MALIGNANT TUMOUR, COMPRISING AGENT DESTROYING VESSELS, AND IMMUNE CONTROL POINT INHIBITOR | 2018 |
|
RU2738369C1 |
| USE OF ANTI-PD-1 ANTIBODY IN PREPARATION OF MEDICINAL AGENT FOR TREATING SOLID TUMOURS | 2020 |
|
RU2825845C2 |
